Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
J. bras. nefrol ; 42(2,supl.1): 4-8, 2020. graf
Article in English | LILACS | ID: biblio-1134833

ABSTRACT

ABSTRACT The Covid-19 pandemic brought several challenges to the healthcare system: diagnosis, treatment and measures to prevent the spread of the disease. With the greater availability and variety of diagnostic tests, it is essential to properly interpret them. This paper intends to help dialysis units concerning the use of clinical criteria and diagnostic tests for decision making regarding the discontinuation of isolation of patients with suspected or confirmed Covid-19, as well as the return to work activities for employees with suspected or confirmed Covid-19.


RESUMO A pandemia da Covid-19 trouxe desafios ao sistema de saúde em diversas esferas: diagnóstico, tratamento e medidas para evitar a disseminação da doença. Com a maior disponibilização e variedades de testes diagnósticos, torna-se fundamental sua adequada interpretação. Este posicionamento pretende orientar unidades de diálise em relação ao uso de critérios clínicos e testes diagnósticos para a tomada de decisão referente à descontinuação do isolamento de pacientes com suspeita ou confirmação de Covid-19, assim como para o retorno às atividades laborais de colaboradores com suspeita ou confirmação de Covid-19.


Subject(s)
Humans , Pneumonia, Viral/diagnosis , Renal Dialysis , Coronavirus Infections/diagnosis , Clinical Laboratory Techniques/standards , Return to Work , Betacoronavirus , Nephrology/standards , Patient Isolation , Pneumonia, Viral/epidemiology , Societies, Medical/standards , Algorithms , Brazil , Urology Department, Hospital/standards , Clinical Laboratory Techniques/methods , Checklist , Pandemics , Real-Time Polymerase Chain Reaction/methods , Clinical Decision-Making , COVID-19 Testing , SARS-CoV-2 , COVID-19
2.
Rev. Inst. Med. Trop. Säo Paulo ; 42(3): 147-52, May-Jun. 2000. tab
Article in English | LILACS | ID: lil-262693

ABSTRACT

Between 1992 and 1997, 790 blood donors with anti-HCV EIA-2 strongly reagent (relationship between the sample optical density/cut-off > 3) detected at the blood bank serological screening, were evaluated in ambulatory environment. They were all negative for Chagas disease, syphilis, hepatitis B (HBsAg) and AIDS. Blood samples were collected at the first ambulatorial evaluation, for hemogram, biochemical tests and new serological tests for HCV (anti-HCV EIA-2). In blood samples of 226 repeatedly reagent anti-HCV EIA-2 blood donors, supplementary "immunoblot" test for HCV (RIBA-2) was used. In 209 donors, the presence of HCV-RNA was investigated by the PCR test. The abdominal ultrasonography was realized in 366 donors. In 269 patients liver biopsy was performed for the histopathological study. The follow-up of blood donors showed that 95.6 percent were repeatedly EIA-2 reagent, 94 percent were symptomless and denied any hepatitis history, with only 2 percent mentioning previous jaundice. In 47 percent of this population at least one risk factor has been detected for the HCV transmission, the use of intravenous drugs being the main one (27.8 percent). Blood transfusion was the second factor for HCV transmission (27.2 percent). Hepatomegaly was detected in 54 percent of the cases. Splenomegaly and signs of portal hypertension have seldom been found in the physical examination, indicating a low degree of hepatic compromising in HCV. Abdominal ultrasound showed alterations in 65 percent of the subjects, being the steatosis the most frequent (50 percent). In 83.5 percent of the donors submitted to the liver biopsy, the histopathological exam showed the presence of chronic hepatitis, usually classified as active (89 percent) with mild or moderate grade in most of the cases (99.5 percent). The histopathological exam of the liver was normal in 1.5 percent of blood donors. The RIBA-2 test and the HCV-RNA investigation by PCR were positive in respectively 91.6 and 75 percent of the anti-HCV EIA-2 reagent donors. The HCV-RNA research was positive in 82 percent of the RIBA-2 positive subjects, in 37.5 percent of the indeterminate RIBA-2 donors and in 9 percent of the negative RIBA-2 donors. Chronic hepatitis has also been observed in 50 percent of the histopathological exams of the anti-HCV EIA-2 reagent donors which were indeterminate RIBA-2...


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Blood Donors , Hepatitis C Antibodies/isolation & purification , Hepatitis C/diagnosis , Hepatitis C/blood , Hepatitis C/epidemiology , Polymerase Chain Reaction/methods , Risk Factors
3.
Rev. Inst. Med. Trop. Säo Paulo ; 42(3): 163-5, May-Jun. 2000. tab
Article in English | LILACS | ID: lil-262696

ABSTRACT

A case of a pregnant patient with chronic hepatitis C who gave birth to monozygotic twins that were infected with HCV is reported. One of the newborns was positive for HCV-RNA in blood sample collected 12 hours after delivery. The other newborn was negative for HCV-RNA at birth, but was detected HCV viremia at three months of age. The results have led to the conclusion that one of the twins was probably contaminated in the intrauterine period, while the other acquired the infection in the perinatal period. Both were negative for HCV-RNA and for anti-HCV in the serum samples collected at nine months of age. The report describes the changes in the laboratory tests conducted in mother and twins until 29 months after delivery.


Subject(s)
Humans , Female , Pregnancy , Infant, Newborn , Infant , Adult , Hepacivirus/isolation & purification , Hepatitis C Antibodies/blood , Hepatitis C/transmission , Infectious Disease Transmission, Vertical , Twins, Monozygotic , Chronic Disease , Follow-Up Studies
4.
Rev. Inst. Med. Trop. Säo Paulo ; 40(5): 335-6, Sept.-Oct. 1998. tab
Article in English | LILACS | ID: lil-225856

ABSTRACT

TTV e um virus DNA recentemente descoberto no Japao a partir de um paciente portador de hepatite pos-transfusional de origem desconhecida. Neste estudo, avaliamos a presenca deste virus em pacientes com hepatopatias cronicas dos estados de Sao Paulo e do Para, representando duas regioes geograficamente diferentes. O DNA do TTV foi encontrado em 21/105 (20 por cento) e 9/20 (45 por cento) dos casos de Sao Paulo e do Para, respectivamente. O sequenciamento do DNA amplificado confirmou a presenca dos genotipos 1a e 2a, bem como de outros genotipos ainda nao descritos ate o momento. Em conclusao, TTV esta presente em casos de hepatopatias cronicas do Sudeste e do Norte do Brasil. por outro lado, maiores estudos ainda sao necessarios antes de se estabelecer relacao causal entre o TTV e a hepatite em seres humanos


Subject(s)
Humans , Communicable Diseases/blood , Blood Transfusion/adverse effects , Blood Donors , Gene Amplification , Hepatitis C, Chronic/diagnosis , Hepatitis B/transmission , Liver Diseases/diagnosis , Sequence Analysis, DNA
SELECTION OF CITATIONS
SEARCH DETAIL